The Stowe Foundation

The work being conducted by Stowe Foundation should eventually receive considerable attention and donations from major US Corporations. We are addressing the very health care problems that come from industrial toxins. It is for this reason the IRS determined that the Stowe Foundation was a 501c3 public charity doing work in the public interest and enjoyed broad public support. This designation puts the Stowe Foundation on the same legal status as the United Way, the American Cancer Society, Habitat for Humanity, and The Salvation Army. The Stowe Foundation intends to contract with a professional fund raising and management-consulting firm Brakeley for example, as we move into a national awareness campaign focused on public support for adult stem cell research. Brakeley is one of America’s top consulting firms for public charities.

Contributions to the Stowe Foundation are tax deductible under section 170 of the Internal Revenue Code.

We are also qualified to receive tax-deductible bequests, devices, transfers or gifts under section 2055, 2106, or 2522 of the Code. The work on adult stem cell transplants and immune therapy is a new beginning for medicine. The donations being brought to the Stowe Foundation will bring hope to all who suffer debilitating illness. Many of the health problems in the United States are directly linked to major industries; the list includes the tobacco industry (emphysema), the alcohol industry (cirrhosis), the fast food industry (diabetes), the chemical and petroleum industry (heart disease and stroke). America produces a vast amount of toxins that inflict major damage to the physical performance of the human body. The Stowe Foundation will bring this knowledge to the US public as part of our mission statement. We refer to the assault on human health as the PITTS Syndrome. The industries that create the toxins bear a moral responsibility to contribute to the cause of restoring health. The Stowe Foundation is the agent of change. The pathway to true health lies through reversing the PITTS Syndrome and incorporating the concepts of Applied BioLogics into mainstream healthcare.

It requires significant financial resources to make the transition from pharmaceutical based medicine to biological medicine. It is more then just supporting the research and development of new product lines and techniques such as adult stem cells and autologous vaccines and biologic response modifiers. All the work in biological medicine must be submitted to the FDA through the Center for Evaluation of Biological Research (CBER). The FDA is prepared for the transition to immune therapy and natural healing, but the technology does not enjoy the financial support of the pharmaceutical industry. Therefore, meeting the regulatory approval process stands as a major roadblock to US citizens enjoying the benefits of biological medicine. The Foundation must turn to public support through fundraisers, to wealthy philanthropic benefactors, to corporate donations and government grants. There is no vested interest in biological medicine except the public interest. The goal of The Stowe Foundation is to act as the agent of change by securing the money that it will take to make the shift. The Foundation will apply those resources through our five operating divisions, the Biotherapy Research Institute, New Horizons Research and Development, Compassionate Care Fund, Public and Professional Education and the Investigational Clinical Studies.

The Stowe Foundation can slowly become self-supporting as the technology behind immune therapy becomes fully developed. The clinical studies being supervised at the BioTherapy Research Institute will prove the efficacy of several novel biological medicines and the adult stem cell technology. Once the clinical study information is publicized, there will be a significant market demand created for the protocols. The demand will outrun the Foundations ability to deliver services. The technology will have to be released beyond the confines of the research centers. It will take a substantial investment on the part of business to build the commercial facilities required to produce the stem cells on a large scale and also to meet the demand for the biologic response modifiers. The Foundation will seek out private enterprise partners who are capable of licensing the technology, producing the products on a commercial scale and marketing the technology to health care providers on an international level. The Stowe Foundation is organized as a non-profit, but it can legally market items to generate revenue to support the on-going operations of the Foundation. This will be particularly beneficial to the Compassionate Care Fund, the New Horizons Research Grants, the Clinical Investigations and the Education Wing of the Foundation. Only the BioTherapy Research Institute has the opportunity to be self-sustaining from its fee for service revenues. The revenues from the licensing fees and royalties on product sales are critical for the sustained success of the Stowe Foundation.

Hydrate2o is one example of a commercial venture (www.hydrate2o.com) that makes donations to the Stowe Foundation to support our work. We hope to attract many more corporate sponsors to reach the goals of the Foundation. The first two tiers of funds put the stem cell technology on the fast track for FDA approval and will determine the fate of the Foundation. Our philanthropic benefactors are underwriting these funds. Success at this level will almost insure that we can get the funds required to complete the regulatory approval process.

The Tier I funds allows us to open the BioTherapy Research Institute and the Applied BioTherapy Center of San Diego to begin the clinical studies on four items; adult stem cell transplants, a powerful new agent for microbial infections, a new cancer control agent and a new method to produce autologous vaccines for viral infections. These trials are critical to meet the regulatory approval process. The Tier I funds also allow us to provide research grants to the university programs that are developing the technology behind adult stem cells. This money is the key to funding the work to find the Universal Pluripotent Adult Stem Cell (UPS) and to conduct the gene therapy work on the UPS cells.

The BioTherapy Research Institute in combination with the Applied BioTherapy Center is also where our very advanced detoxification protocols can be applied. The Center will be available to treat anyone who wants to receive immune therapy on a fee for service basis. The protocols are very effective to reverse chronic illnesses such as diabetes, heart disease, cancer, arthritis, fibromyalgia, hepatitis C, lymes and most conditions triggered by the PITTS Syndrome. The Center will also be able to offer the best in anti-aging medicine. The Applied BioTherapy Center is the entry point for US citizens who wish to participate in the program. This can be run and operated as a for profit entity, with the Foundation benefiting from the sale of the biological products produced by the BioTherapy Research Institute.

Ultimately the Stowe Foundation will want to license the technology platform to commercial operations; one to provide cell therapy products and procedures to medical systems around the world and the second to market the biological medicines into pharmacies and clinics.

This underscores the need to make sure all protocols and procedures meet FDA standards. The royalties to the Foundation are the means by which the Stowe Foundation can become self funded to provide immune therapy for the indigent through the work of the Compassionate Care arm of the Foundation and to carry out ongoing research and development activities though the New Horizons R&D division.

The financial requirements of the Stowe Foundation can be broken down by project and activity. I have also put these in relative order of priority. As with any funding proposal, the benefactor to the Foundation may wish to discuss the objective of their donation. The Foundation will honor any request made as its regards a designation to any one of the five divisions. Without a designation, the Stowe Foundation will apply the donation to its priority needs.

There are five divisions of the Stowe Foundation. Each has its own operating budget and mission statement. The divisions carry out the work of the Foundation as our financial resources allow. The five divisions under the Foundation’s umbrella are:

1. The BioTherapy Research Institute
The BioTherapy Research Institute is the facility where patients can be treated with immune therapy. It is the workhorse of the Foundations quest to end chronic illness. The protocols are centered on the immune system or the body’s natural ability to heal itself. Biological medicines are used to manage the immune response and to target the immune system onto abnormal tissue such as cancer or viral infections such as hepatitis C. All chronic illness has been traced to the PITTS Syndrome, which can be resolved with the theories of Applied BioLogics (the rationale application of biological medicine). The PITTS Syndrome represents the five categories of human physiology that can suppress the immune system.

P – Poor Nutrition
I – Infections
T - Toxins
T – Trauma
S – Stress

By resolving the PITTS Syndrome with Applied BioLogics the body can heal itself through the immune system. The adult stem cells are probably the most dramatic demonstration of the body’s ability to heal through the generation of new tissue. Type II Diabetes is a classic example of a chronic illness that can be resolved with Applied BioLogics.

1. The diet can be altered to control blood glucose metabolism.
2. The pancreas can be cleared of the toxins and the infections that stop the production of
insulin.
3. Biologic response modifiers and natural plant extracts such as aloe vera can be used to
overcome insulin resistance.
4. Physical trauma to the body can be repaired with adult stem cells
5. Emotional trauma is overcome through spiritual counseling
6. Lifestyle choices eliminate stress.

Once the PITTS Syndrome has been resolved, then the adult stem cells can regenerate a new pancreas and diabetes is eliminated. Applied BioLogics is the science of healing the mind, body, spirit and emotions. The Stowe Foundation has authored a comprehensive description of Applied BioLogics available under a separate cover.

2. Compassionate Care Fund
Many patients in need of immune therapy simply cannot afford the fee for service aspect of the BioTherapy Research Institute. Most insurance policies do not cover immune therapy as it is considered experimental and the FDA has not approved most biological medicines. Medicare does not cover the costs of experimental therapy. Hence the Stowe Foundation has set up our Compassionate Care Fund and patients in need of financial assistance are provided funds, as they are available. The Stowe Foundation conducts regular fundraisers on behalf of the compassionate care fund. A cancer patient that requires an intensive immune therapy program typically spends $60,000 to $75,000 per four month cycle of therapy. This does not include the costs of stem cell transplants. The stem cells can add another $50,000 and require travel outside of the United States. While $125,000 is a very large out of pocket expense and multiple cycles may be required, it is a small dollar amount compared to the average cost of cancer therapy. The work being done with the new biologic response modifiers may significantly reduce these costs. In Fort Worth Texas, the Stowe Foundation has worked with the oncology team at Cooks Children Hospital to make immune therapy available as support therapy to a teenage lymphoma patient. One goal of the Stowe Foundation is to make Integrative Medicine a reality.

3. Public and Professional Education
The Foundation has a goal to educate the public and professional healthcare providers about the power of the immune system. The Foundation sponsors free health seminars at cities around the USA and Canada regarding immune therapy and Applied BioLogics. Dr. Stowe also lectures at professional conventions where doctors receive CME credits (Continuing Medical Education) for attending his lectures on immune therapy and biological medicine. Dr. Stowe has plans to publish several books, one on the PITTS Syndrome, a second on Applied BioLogics and a series of short books and tapes entitled Survive Until a Cure, which will feature techniques for using immune therapy to survive cancer, heart disease, diabetes, arthritis, fibromyalgia and other autoimmune disorders. The proceeds from the book sales will help fund the other activities of the Foundation. The Foundation would also like to expand its information technology capabilities on the Internet and perhaps host a radio talk show on health and wellness. ABC, which owns many of the premier am radio stations across America, has shown interest in a syndicated talk show on natural healing techniques. The initial pilot could be recorded at WBAP (820 AM) in Dallas/Ft. Worth. If funds were available, The Stowe Foundation would underwrite the initial production costs and purchase airtime to establish the show.

4. Clinical Investigations of Applied BioLogics
The Foundation sponsors independent investigations and clinical trials into the immune therapy protocols advocated by the BioTherapy Research Institute. The trials are designed to meet the standards of the FDA and NIH for outcome based studies. Outcome based studies allow the Foundation to utilize patient specific immune therapy protocols and the studies do not have to be double blind or have randomized control groups. Along these lines of clinical investigations, the Foundation has been approached by the NIH to participate in a far-reaching study of immune therapy and cancer.

The costs of Dr. Fink’s investigation of the adult stem cell transplants are budgeted at eighteen million dollars ($18,000,000). This is a relatively small number of patients (120) and is a phase II study of safety and efficacy.

Phase III is projected to be 10 times larger (1,200 patients) and will be more expensive when the study is moved from Mexico (Angeles Hospital) to the United States (using University hospitals in the US). The phase III costs can be expected to reach three hundred million ($300,000,000). This is the stage where large corporate donations will be needed to support the Stowe Foundation. But the Foundation is a 501c3 public charity and all donations will be a tax benefit to the donor. The Foundation will retain the services of a professional fund raising organization, i.e. Brakeley, to meet these goals.

The clinical investigations sponsored by the Stowe Foundation will eventually be expanded to include the autologous vaccines and biological medicines that can be generated in the molecular biology lab to fight cancer, viral infections and many of the autoimmune disorders. These clinical studies are a necessary part of eventually licensing the technology to a commercial partner. Royalties derived from the technology transfer will be applied to the ongoing activities of the Foundation.

5. New Horizons Research and Development Grants
The Foundation is constantly evaluating advances being made in the field of immune therapy. Because the entire field of biological medicine and immune therapy is an emerging science, there is no large source of funds available to sustain research and development in technology like biologic response modifiers, autologous vaccines and adult stem cells. No industry in the United States has a vested interest in biological medicine to sustain a research and development program. Every company that gets involved in biological medicine is a start-up. The Stowe Foundation constantly analyzes opportunities where we might be able to make a difference in bringing critical new products to the patients. Our status as a 501c3 allows us to make grants to support research and development of immune therapy protocols. We have a strong affiliation with the key research scientists at major universities that are doing the groundbreaking work on adult stem cells and other forms of biological medicine. The Stowe Foundation acts as a testing facility where new ideas can be evaluated for their ability to heal the body. Eventually we will need our own research campus to consolidate the work that is being carried out at multiple locations. We are unique in that many ideas flow through our organization and we integrate the information into a comprehensive immune therapy protocol. That is the role of the BioTherapy Research Institute. To my knowledge we are the only such facility in existence.